
If approved, this treatment would offer a new option for the nearly one million Americans living with MS

The results from a global phase 3 trial show the longest survival data ever reported in this setting

This is the first oral drug treatment for this rare disease in adults

The approval was based on phase 3 trial results showing a 56% risk reduction in disease progression

The 2026-2027 vaccine targets the XFG variant to more closely match current variants

This is the first new regimen in more than a decade for first-line treatment for this type of breast cancer

The treatment uses peptides designed to retrain the immune system to tolerate peanuts

The treatments are for eligible adults in England and Wales

More than 186,000 men are diagnosed each year with mHSPC globally

Asthma affects over 360 million people worldwide, including over 40 million people in Europe

The company will gain a novel oral treatment for lung cancer

Mezigdomide improves progression-free survival in patients with relapsed or refractory multiple myeloma